Employer profile
Sms Clinical Research
1 certified H-1B filings across 1 fiscal year.
FY2023 filings
1
FY2023 median
$57k
Top role
Clinical Research Director
1 filings
Top state
TX
1 filings
Sms Clinical Research has filed 1 certified H-1B Labor Condition Applications over FY2023. In FY2023, its median certified base salary was $57k ($57k–$57k interquartile range). The most-filed role is Clinical Research Director (1 filings).
Year-over-year
How Sms Clinical Research hired across H-1B fiscal years. YoY column compares to the prior FY.
| FY | Filings | Median $ | YoY % |
|---|---|---|---|
| FY2023 | 1 | $57k | — |
Top job titles
Most-filed positions, across all years (raw DOL titles).
| Job Title | Filings | Median |
|---|---|---|
| Clinical Research Director | 1 | $57k |
Top worksite states
Where this employer files.
| State | Filings | Median |
|---|---|---|
| TX | 1 | $57k |
Prevailing wage level distribution
DOL Levels I–IV approximate experience tiers (I = entry, IV = fully competent). A heavy Level I/II skew suggests entry-level / contractor-style hiring; a heavy IV skew suggests senior in-house roles.
Lvl I
1100%
Frequently asked questions
- Does Sms Clinical Research sponsor H-1B visas?
- Yes. Sms Clinical Research has filed 1 certified H-1B Labor Condition Applications (LCAs) over FY2023. An LCA is a required step before an employer files an H-1B petition; a certified LCA does not by itself guarantee an approved visa.
- What is the median H-1B salary at Sms Clinical Research?
- In FY2023, the median certified H-1B base salary at Sms Clinical Research was $57k, with a 25th–75th percentile range of $57k–$57k. This is the annual base wage stated on the LCA and excludes bonus, equity, and other compensation.
- What jobs does Sms Clinical Research hire H-1B workers for?
- Sms Clinical Research's most-filed H-1B role is Clinical Research Director (1 filings). Its top worksite state is TX.
- How many H-1B filings did Sms Clinical Research submit in FY2023?
- Sms Clinical Research had 1 certified H-1B LCA filings in FY2023.